Liquid biopsy firm Lexent Bio recently announced a non-exclusive partnership with Illumina to develop an in vitro diagnostic kit for cancer.

Danaher announced Wednesday that its wholly owned subsidiary DH Europe Finance has priced its offering of $3.97 billion senior notes.

Waters posted revenues of $577.3 million in Q3 compared to $578.0 million in Q3 2018 and falling short of the average Wall Street estimate of $588.9 million.

The Stratum Foot Plating System is the next generation of anatomic locking plates designed to optimize ease of use and reduce operating time.

A new study from the University of South Australia researchers found the number of people that die from bowel or colorectal cancer (CRC) would be much higher without pre-diagnostic colonoscopies.

Qiagen and Illumina just made a huge commitment to one another. The two companies announced a 15-year partnership to broaden the availability and use of NGS-based in-vitro diagnostic kits, including companion diagnostics, for patient management.

Researchers from the University of Strathclyde have developed a blood test that could help to accelerate the diagnosis of brain cancer.

Roche has won a nod from FDA for a new diagnostic for individual blood donation testing. The Basel-Switzerland-based company’s cobas Babesia test is for use on the cobas 6800 8800 system.

In diagnostics these days, “a lot of people are after plasma,” reports Jim Averso, vice president, sales and marketing, of I.W. Tremont.

Bio-Techne said recently that its fiscal 2020 first quarter revenues rose 12 percent year over year, driven by growth in each of its business segments.

The National Institutes of Health has awarded researchers at the University of Virginia a $2.7 million grant to investigate how variation in a specific gene, called ID3, influences atherosclerosis.

Genialis recently announced a comarketing agreement with Thermo Fisher Scientific on data analysis for RNA sequencing.

Exact Sciences reported after the close of the market recently that its third quarter revenues rose 85 percent year over year, thanks to an 89 percent increase in testing volumes for its Cologuard colorectal cancer screening test.

LexaGene said recently that it has closed a previously announced financing round, grossing C$6.7 million (US$5.1 million).

Korean rare disease diagnostics firm 3billion said this week that it has raised $10 million in a Series B financing round.